Skip to main content
Premium Trial:

Request an Annual Quote

Noviscend Inks Canadian Distribution Deal for Myriad Genetics Tests

NEW YORK — Medical technology firm Noviscend said on Monday that it has signed an agreement to exclusively distribute certain of Myriad Genetics' genetic tests in Canada.

According to Ontario-based Noviscend, the deal covers the EndoPredict breast cancer recurrence test; myRisk and myRisk – Hereditary and Single Gene Panel for hereditary cancer risk; myChoiceCDx test for homologous recombination deficiency status in ovarian cancer patients; the GeneSight pharmacogenomic test for patients with depression; and Prolaris for evaluating prostate cancer aggressiveness.

Additional terms of the deal were not disclosed. 

Earlier this year, Salt Lake City-based Myriad divested its pharma research services business, as well as its Vectra DA rheumatoid arthritis test and its myPath Melanoma test as part of a restructuring effort.